Evidence map›Paper›PMID 41691543›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2026

A scalable new model of germline cancer genomic care delivery: Assessing psychological outcomes.

Ilana B Solomon, Patrick Boyd, Yi Xiao, Kathryn R Dang, Ashley Mochizuki, Madeline Currey, Michael Garcia, Marilan Luong, Frances Cheung, Stephen B Gruber and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ilana B SolomonDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA.
Patrick BoydDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Beckman Research Institute, Duarte, CA. Electronic address: paboyd@coh.org.
Yi XiaoDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
Kathryn R DangDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA.
Ashley MochizukiDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA.
Madeline CurreyUniversity of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
Michael GarciaDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
Marilan LuongTransplantation and Cellular Therapy, Children's Hospital Los Angeles, Los Angeles, CA.
Frances CheungDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
Stephen B GruberDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA; Beckman Research Institute, Duarte, CA.
Heather HampelDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA.
Sarah LabibUniversity of Arizona College of Medicine, Phoenix, AZ.
Angela MakVirginia Tech Carilion School of Medicine, Roanoke, VA.
Ran QiaoDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
Sarah TangCalifornia Northstate University, College of Medicine, Elk Grove, CA.
Sandra DaveyDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Beckman Research Institute, Duarte, CA.
Stacy W GrayDivision of Clinical Cancer Genomics, City of Hope National Medical Center, Duarte, CA; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA; Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA; Beckman Research Institute, Duarte, CA; System Strategy Office, City of Hope National Medical Center, Duarte, CA.

Funding

Scalable tools to effectively translate genomic discoveries into the clinic : Administrative SupplementR35HG010721 · NHGRI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GRAY, STACY W. · 2019 to 2024
$3.1M
NHGRI NIH HHS R35 HG010721
6 · The paper itself

Abstract

purposeNew care models promise to increase access to germline genetic testing. To decrease testing gaps, we offered universal germline testing without pretest genetic counseling to unselected patients at a comprehensive cancer center. To address safety concerns over the elimination of pretest counseling, we examined detrimental psychological impact (DPI) after participants underwent testing in this novel model.

methodsWe assessed participants' genomic testing-specific DPI using the Feelings About Genomic Testing Results instrument (2-weeks/6-months after disclosure). Overall DPI, negativity, uncertainty, positivity, and privacy concerns were assessed. We used chi-square, analysis of covariance multivariable regression, and mediation analysis to examine relationships between variables.

resultsA total of 846 participants completed the survey. Most participants (96.0%) exhibited low DPI, negativity (95.6%), uncertainty (94.0%), and concerns about privacy (95.6%) and high positivity (55.6%). Participants with cancer had higher negativity and uncertainty than those without. DPI significantly diminished over time in participants with positive tests.

conclusionOverall DPI was low, demonstrating that most participants are at minimal psychological risk when receiving germline results without pre-test counseling. However, a small subset of participants exhibit high distress and uncertainty. Additional efforts are needed to identify at-risk participants receiving universal testing who would benefit from interventions aimed at mitigating DPI.

Indexed as

Genetic TestingNeoplasmsAdultAgedDelivery of Health CareFemaleGenetic CounselingGenetic Predisposition to DiseaseGenomicsGerm CellsGerm-Line MutationHumansMaleMiddle AgedSurveys and QuestionnairesUncertaintyGenetic servicesHereditary cancer syndromesOncologyPsychological outcomes

Identifiers

PMID41691543
PMCPMC13638032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.